2022 Pharma Contract Services Industry Outlook

Outcome Capital shares their analysis and insights on pivotal trends and opportunities within the Pharma Contract Services sector.

View Resource

2022 Digital Health Sector: Highlights, Trends & Opportunities

Outcome Capital shares their analysis and insights on pivotal trends and opportunities within the Digital Health sector.

View Resource

2022 Medical Device Sector: Highlights, Trends & Opportunities

Outcome Capital shares their views, insights and data on key strategic trends and dynamics in the Medical Device sector.

View Resource

2022 Biopharma Industry Outlook: Highlights, Trends & Opportunities

Outcome Capital shares their views, insights and data on key strategic trends and dynamics in the biopharma sector. This segment is poised for significant growth, scientific advancement and consolidation.

View Resource

2022 Life Science Consulting Sector: Market Trends, Dynamics & Opportunities

Outcome Capital shares their views, insights and data on key strategic trends and dynamics in the life science consulting sector. This vibrant segment is poised for significant growth and consolidation.

View Resource

Digital Health Sector: Trends and Opportunities

Outcome Capital shares their views, insights and data on key strategic and financial trends within the Virtual Care, Population Health and Tech-Enabled Payor segments. These vibrant segment niches of the broader Digital Health industry are poised for significant investment and consolidation.

View Resource

Biology & Digital Technology Merger Gives Rise to Spatial Biology

As a highly specialized life science advisory and investment banking firm, Outcome Capital looks to identify emerging trends that effect how researchers and clinicians understand, diagnose, and treat disease.

View Resource

Shining the Light on Diagnostic Shortcomings During the COVID Pandemic Reveals a Stronger Path for the Future

Outcome Capital sat down and spoke with Dr. Cathy Petti to get her perspective on the shortcomings of COVID diagnosis and how to carve out a stronger path for the future. 

View Resource

Grabbing Hold of the COVID-19 Pandemic as a Diagnostic Company

Outcome Capital sat down and spoke with Chuck Morrison to get his thoughts on the effects of the current COVID-19 pandemic on diagnostic transactional activity in 2020 and how best to weather the economic environment.

View Resource

In Vitro Diagnostic Market Insight: Continued Growth and Consolidation

The In Vitro Diagnostic market values established companies with regulatory approval and market traction. This is demonstrated by premiums paid for acquisitions of companies that offer the opportunity to quickly capture market share and IPOs of companies with significant revenues.

View Resource

Update in Immuno-Oncology: Multiplicity of Drug In-Licensing Opportunities to Expand Your Pipeline

This market update captures assets currently in development and recent partnering/in-licensing transactions which can catalyze development and improve valuation for companies.

View Resource

Ophthalmology Market: Opportunity for Growth Remains

The ophthalmology market values innovation approaches, demonstrated by premiums paid for acquisition of  first-in-class therapies and public market support of ophthalmology gene therapy companies.

View Resource

Cell-based Therapies: A Maturing Market Poised for Growth

The cell-based therapy market will grow significantly, supported by recent clarity in the FDA pathway, improved clinical outcomes as well as market entry by big pharma.  

View Resource

Contact Us for More Information

Would you like to learn more about working with Outcome Capital or discuss your specific needs?

Contact Us

  • Boston

    99 High St. Suite 2900, Boston, MA 02110
    (617) 431-2278